Posted by Michael Wonder on 23 Feb 2023
Vir Biotechnology announces positive final draft guidance on sotrovimab from the UK’s NICE
22 February 2023 - Final draft guidance based on cost effectiveness evaluation of sotrovimab.
Vir Biotechnology today announced that the UK’s NICE provided positive final draft guidance recommending the use of sotrovimab, an investigational SARS-CoV-2 neutralising monoclonal antibody, in adults who do not need supplemental oxygen for COVID-19 and who have an increased risk for progression to severe COVID-19 where nirmatrelvir and ritonavir (Paxlovid) is contra-indicated or unsuitable.
Due to existing inventory, no meaningful additional sales of sotrovimab in the UK are anticipated in 2023.
